Question special

Previous studies have shown increased ACE2 expression after treatment with ACEi/ARB as well as MRA/ARA’s (Brojakowska et al, 2020: . Your analysis showed no difference in risk of infection or severe disease in patients treated with ACEi/ARB. Though a much smaller and sicker population, do you expect to see increased risk of infection in patients treated with both ACE/ARB and ARA's with the thought that treatment with both may lead to greater expression of ACE2?